Holocene Advisors Adds $67M in iRhythm Holdings, Inc. ($IRTC)

Holocene Advisors made a substantial increase in its stake in iRhythm Holdings, Inc. (NasdaqGS: IRTC), as revealed in its latest SEC filing. The firm added 565,090 shares, boosting its holdings by 82.7% to a total of 1,248,658 shares valued at approximately $147.9 million as of the reporting date.

What Changed in Holocene Advisors' iRhythm Holdings Position

Holocene Advisors increased its position in iRhythm Holdings by 82.7%, adding 565,090 shares to bring its total to 1,248,658 shares. The investment is now valued at about $147.9 million. This significant increase reflects a strong confidence in the company's future prospects.

Other Institutional Activity in iRhythm Holdings

BlackRock, Inc. trimmed its holdings by 72,484 shares, ending with 2,741,505 shares worth approximately $323.6 million. Meanwhile, Vanguard Portfolio Management LLC opened a new position with 1,796,372 shares valued at $212 million. RTW Investments, LP increased its stake by 486,510 shares, reaching a total of 1,668,500 shares valued at around $196.9 million. Millennium Management LLC also boosted its position significantly by 781,638 shares, totaling 1,608,014 shares worth approximately $189.8 million. Artisan Partners Limited Partnership reduced its holdings by 61,085 shares, leaving it with 1,450,907 shares valued at about $171.2 million.

iRhythm Holdings, Inc. Stock Down 1.1%

Shares of iRhythm Holdings traded near $118.42 on Tuesday. The company has a market capitalization of approximately $3.91 billion and a forward P/E ratio of 113.1, indicating high growth expectations. With a beta of 1.281, the stock has shown volatility. Its 52-week range spans from $100.85 to $212.00, with a 50-day moving average of $115.54 and a 200-day moving average of $148.74. The company maintains a strong liquidity position with a current ratio of 5.166 and a quick ratio of 4.785, though its debt-to-equity ratio is relatively high at 452.386.

Recent Earnings

iRhythm Holdings reported revenue of $787.9 million, reflecting a growth rate of 25.7%. However, the company is not yet profitable, with a net margin of -3.5% and a return on equity of -22.4%. The company is expected to announce its next earnings on July 30, 2026.

Insider Buying and Selling at iRhythm Holdings, Inc.

Recent insider activity at iRhythm Holdings includes sales by Chief Accounting Officer Marc Wade Rosenbaum and EVP Chief Risk Officer Sum Shrishrimal, each selling shares on June 2, 2026. However, on May 29, 2026, several executives, including President and CEO Quentin Blackford, purchased shares at an average price of $96.82, indicating potential confidence in the company's future.

Analysts Set New Price Targets

Analysts have been maintaining a positive outlook on iRhythm Holdings. On June 22, 2026, BTIG reiterated a buy rating with a target price of $185. Canaccord Genuity maintained its buy rating with a target of $152 on June 1, 2026. B of A Securities and Citigroup also maintained buy ratings, with target prices of $180 and $157, respectively. Overall, the consensus among 14 analysts is strong buy, with a mean target price of $178.93.

About iRhythm Holdings

iRhythm Holdings, Inc., based in San Francisco, California, specializes in digital healthcare solutions. The company develops and markets device-based technology for ambulatory cardiac monitoring to diagnose arrhythmias. Its main product, the Zio suite of services, includes long-term and short-term continuous monitoring and mobile cardiac telemetry. iRhythm is led by CEO Quentin S. Blackford and employs around 2,400 people.

Bottom Line

Holocene Advisors' increased stake in iRhythm Holdings suggests a strong belief in the company's potential. While 13F filings are backward-looking and may not reflect the current position, they offer insight into institutional sentiment. iRhythm's innovative healthcare solutions and positive analyst outlook make it a stock to watch, despite its current lack of profitability.